#United States #New York #Faruqi & Faruqi #James Wilson #Tvardi Therapeutics

Investor Deadline Approaching: Taking Action for Tvardi Therapeutics Investors

Faruqi & Faruqi, LLP, a prominent national securities law firm, has recently initiated an investigation regarding potential claims on behalf of investors in Tvardi Therapeutics, Inc. This inquiry comes in light of significant losses sustained by investors following a sharp decline in the company's stock price. On October 13, 2025, Tvardi Therapeutics experienced a staggering drop of over 80% after releasing disappointing preliminary data from its Phase 2 REVERT clinical trial of TTI-101, designed for idiopathic pulmonary fibrosis.

Understanding the Situation

The REVERT trial was expected to offer insights into the safety and efficacy of TTI-101, particularly regarding its impact on lung function. However, preliminary results revealed that the trial did not meet its anticipated goals, leading to investor panic and a dramatic sell-off. This critical drop raised concerns among shareholders, prompting Faruqi & Faruqi to step in and offer assistance.

Faruqi & Faruqi's Securities Litigation Partner, James (Josh) Wilson, has encouraged any investors who have suffered substantial losses in Tvardi's stock to reach out directly. Their team aims to discuss potential legal avenues available to recover losses incurred during this tumultuous market period. For investors looking for clarity and guidance, Wilson's direct phone lines include 877-247-4292 or 212-983-9330 (Ext. 1310).

What Investors Should Know

Investors may be unaware of the legal options available to them following such significant losses. Faruqi & Faruqi, which has had a history of recovering hundreds of millions of dollars for investors since its inception in 1995, provides a beacon of hope. They offer a comprehensive analysis of the claims process and what steps investors can take to pursue justice and accountability from the parties involved.

Potential claims may revolve around whether Tvardi Therapeutics had sufficiently disclosed material information regarding the trial's prognosis and its implications on stock performance. If there was a failure to adequately inform shareholders about the risks associated with the product’s trial, this could lead to a case of securities fraud.

Why This Matters

The situation surrounding Tvardi Therapeutics is a crucial reminder for investors about the volatility of the stock market and the responsibilities companies hold in terms of transparency. The REVERT trial's results highlight the importance of understanding clinical study outcomes and ensuring that organizations maintain steady communication with their investors. Legal firms like Faruqi & Faruqi play an essential role in safeguarding investor interests and holding entities accountable for negligent practices.

What to Do Next

Investors in Tvardi Therapeutics should not hesitate to take action if they have experienced financial setbacks. Contacting legal representatives who specialize in securities law, such as Faruqi & Faruqi, is a proactive step toward potentially recovering lost investments.

As this situation develops, it's crucial for affected investors to stay informed and actively engage with legal counsel. To learn more about the investigation or to discuss an individual case, visit Faruqi & Faruqi's official website or contact James Wilson directly for personalized assistance and guidance.

By taking these steps, investors can gain clarity on their rights and the available paths forward amid the uncertainties posed by market fluctuations.